Aptevo details warrant terms as mipletamig shows 79% TP53-AML remission, $8.3M cashNov 17Clinical readoutAptevo TherapeuticsAscentage Pharma Group InternationalUpdated
Cullinan reports Q3 2026 results, flags December CLN-978 data and zipalertinib NDA progressNov 10Quarterly updateBlossomHill TherapeuticsCLN-978
Roche registers giredestrant Phase 3 trial; six other studies updateNov 6Weekly roundup, 16 itemsAbbViealectinibUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Syndax reports Q3 2026 results, 90% Revuforj revenue growth, CFO transitionNov 2Quarterly updaterevumenibSyndax Pharmaceuticals Inc
AbbVie posts results for Japan CLL/SLL study; also files new Phase 3 NSCLC trial vs pembrolizumabOct 23Weekly roundup, 6 itemsABBV-1480AbbVieUpdated
Sanofi's NKCE trial SAR443579 in AML halted early; results posted for terminated studyOct 23Weekly roundup, 6 itemsBayerdiclofenac
MD Anderson trial of azacitidine plus venetoclax maintenance in AML stopped for low enrollmentOct 16Trial updateazacitidineRoche
Nurix reports Q3 2026 results as bexobrutideg enters Phase 3 and NX-2127 is droppedOct 13Quarterly updatebexobrutidegNurix Therapeutics, Inc.
Aptevo reports frontline AML data for mipletamig, targets Phase 2 talks in early 2027Aug 14Quarterly updateAptevo Therapeutics
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026Aug 12Quarterly updateKura Oncology, Inc.ziftomenib
Cullinan reports Q2 2026 results, outlines T cell engager trial timelinesAug 6Quarterly updateCullinan Therapeutics Inc.
Syndax reports 2Q26 revenue growth, details EGFR and menin inhibitor pipeline additionsAug 4Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Moleculin reports 37% blinded CRc in venetoclax-failed AML patients from MIRACLE trialJul 31Clinical readoutMoleculin Biotech, Inc.venetoclax
AbbVie week: BOTOX oral pain results post; new CLL, myeloma, ABBV-859 trials filedJul 31Weekly roundup, 6 itemsABBV-859AbbVie
Cullinan Therapeutics registers Phase 1b trial of CLN-049 with azacitidine, venetoclax in AMLJul 23Trial updateazacitidineCLN-049